SCHEMBL8047274

SCHEMBL8047274

CC(C)COc1ccc(CCO)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 4/20 0.52
MAPT P10636 2/20 0.50
MEN1 O00255 1/20 0.50
ALOX12 P18054 1/20 0.50
KMT2A Q03164 1/20 0.50
PTGS2 P35354 1/20 0.48
POLB P06746 1/20 0.46
HPGD P15428 1/20 0.46
XBP1 P17861 1/20 0.46
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PPARA Q07869 1/20 0.45
ADRB2 P07550 2/20 0.44
ADRB1 P08588 2/20 0.44
LMNA P02545 1/20 0.44
NR3C1 P04150 1/20 0.44
CYP2D6 P10635 1/20 0.44
ADRA1A P35348 1/20 0.44
CYP2J2 P51589 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8048422 0.84 MAPT (0.53) ACACBMAPTMEN1ALOX12KMT2A
SCHEMBL9437679 0.84 CA2 (0.46) KMT2ACYP4F2CYP4A11PPARAADRB2
SCHEMBL20780568 0.82 ACACB (0.50) ACACBMAPTMEN1ALOX12KMT2A
SCHEMBL27729574 0.82 KMT2A (0.51) ACACBMAPTMEN1ALOX12KMT2A
SCHEMBL4738384 0.81 CYP2C9 (0.46) PTGS2CYP4F2CYP4A11PPARAADRB2
SCHEMBL27805471 0.81 TDP1 (0.58) MEN1KMT2APTGS2CYP4F2CYP4A11
SCHEMBL123415 0.81 MAPT (0.55) ACACBMAPTMEN1ALOX12KMT2A
SCHEMBL8047271 0.81 ACACB (0.52) ACACBMAPTMEN1ALOX12KMT2A
SCHEMBL20739975 0.81 ACACB (0.49) ACACBMAPTMEN1ALOX12KMT2A
SCHEMBL11157593 0.81 TAAR1 (0.57) ACACBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11440884-B2 Compounds, salts thereof and methods for treatment of diseases ACADIA PHARMACEUTICALS INC. (US) 2022-09-13 US disclosed
US-20210122713-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2021-04-29 US disclosed
EP-3672960-A2 COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES Acadia Pharmaceuticals Inc. (US) 2020-07-01 EP disclosed
WO-2019040104-A2 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2019-02-28 WO disclosed
US-6106999-A SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS MITSUI CHEMICALS (JP) 2000-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11440884-B2 Compounds, salts thereof and methods for treatment of diseases SLC10A1, VHL, CYP11B2 ACACB 759/4885MAPT 1266/4885MEN1 264/4885
US-20210122713-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES SLC10A1, VHL, CYP11B2 ACACB 759/4885MAPT 1266/4885MEN1 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.